Get the Stockscreener App
11.84
3.27%
-0.40
Wave Life Sciences Ltd Stock (WVE) Latest News
Wave Life Sciences begins Phase 1 obesity trial - MSN
Wave Life Sciences Announces Initiation of Phase 1 INLIGHT Clinical Trial of WVE-007 in Obesity - GlobeNewswire
Revolutionary Once-Yearly Obesity Drug Enters Human Trials: Wave's WVE-007 Takes On Wegovy - StockTitan
Wave Life Sciences Ltd. (NASDAQ:WVE) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Wave Life Sciences Ltd. (NASDAQ:WVE) Given Average Recommendation of “Buy” by Brokerages - Defense World
BlackRock, Inc. Expands Stake in WAVE Life Sciences Ltd - GuruFocus.com
Wave Life Sciences Ltd (WVE) requires closer examination - US Post News
Wave Life Sciences (NASDAQ:WVE) Stock Price Down 3.6%What's Next? - MarketBeat
Is Wave Life Sciences Ltd (WVE) positioned for future growth? - SETE News
Wave Life Sciences (NASDAQ:WVE) shareholders have earned a 69% CAGR over the last three years - Yahoo Finance
Raymond James gives a Strong buy recommendation for Wave Life Sciences Ltd (WVE) - Knox Daily
China Universal Asset Management Co. Ltd. Boosts Stock Position in Wave Life Sciences Ltd. (NASDAQ:WVE) - MarketBeat
Wave Life Sciences Ltd. (NASDAQ:WVE) Shares Purchased by Moody Aldrich Partners LLC - MarketBeat
SG Americas Securities LLC Boosts Holdings in Wave Life Sciences Ltd. (NASDAQ:WVE) - Defense World
Where are the Opportunities in (WVE) - Stock Traders Daily
Wave Life Sciences (NASDAQ:WVE) delivers shareholders enviable 72% CAGR over 3 years, surging 8.5% in the last week alone - Simply Wall St
(WVE) Trading Advice - Stock Traders Daily
JPMorgan Chase & Co. Sells 16,382 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE) - Defense World
Wave Life Sciences Updates Corporate Presentation in 8-K Filing - Defense World
Wave Wants To Put The Joy Back Into Weight-Loss Drugs - Citeline
Is Wave Life Sciences (WVE) the Top Small Cap Stock to Buy with the Highest Upside Potential? - Yahoo Finance
Wave Life Sciences Highlights Strategic Priorities and Expected 2025 Milestones Ahead of J.P. Morgan Presentation - GlobeNewswire
Wave Life Sciences Advances Obesity Drug WVE-007, Reports Strong DMD Treatment Results - StockTitan
Barclays PLC Has $1.31 Million Stock Position in Wave Life Sciences Ltd. (NASDAQ:WVE) - MarketBeat
Top 10 Small Cap Stocks to Buy with the Highest Upside Potential - Insider Monkey
WAVE Life Sciences (FRA:1U5) Cash From Discontinued Investi - GuruFocus.com
Wave Life Sciences Ltd. (NASDAQ:WVE) Given Average Recommendation of “Buy” by Analysts - Defense World
Wave Life Sciences Ltd. (NASDAQ:WVE) Receives $22.22 Average Target Price from Brokerages - MarketBeat
12 Best Growth Stocks Under $25 to Buy Now - Insider Monkey
Is Wave Life Sciences Ltd. (WVE) the Best Growth Stock to Buy Now Under $25? - Yahoo Finance
How to Take Advantage of moves in (WVE) - Stock Traders Daily
Wave Life Sciences Is A Buy On Pipeline Prospects (WVE) - Seeking Alpha
Wave Life Sciences (NASDAQ:WVE) Trading Down 4%Here's What Happened - MarketBeat
Wave Life Sciences (NASDAQ:WVE) Stock Price Up 7.7%What's Next? - MarketBeat
Franklin Resources Inc. Cuts Stock Position in Wave Life Sciences Ltd. (NASDAQ:WVE) - Defense World
Learn to Evaluate (WVE) using the Charts - Stock Traders Daily
Wave Life Sciences Ltd. (NASDAQ:WVE) Shares Purchased by Barclays PLC - MarketBeat
Geode Capital Management LLC Increases Stock Holdings in Wave Life Sciences Ltd. (NASDAQ:WVE) - MarketBeat
Barclays PLC Acquires 100,498 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE) - Defense World
Wave Life Sciences (NASDAQ:WVE) Stock Price Down 2.6%Here's Why - MarketBeat
Wave files clinical trial application for WVE-007 - BioWorld Online
State Street Corp Has $19.03 Million Stock Holdings in Wave Life Sciences Ltd. (NASDAQ:WVE) - MarketBeat
Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-007 (siRNA Targeting INHBE) in Obesity - The Manila Times
Wave Life Sciences Announces Submission of First Clinical - GlobeNewswire
Wave Life Sciences Advances Novel Obesity Drug WVE-007 Targeting INHBE Gene; Clinical Trials Set for 2025 - StockTitan
XTX Topco Ltd Buys Shares of 15,334 Wave Life Sciences Ltd. (NASDAQ:WVE) - Defense World
WAVE Life Sciences (FRA:1U5) Other Long-Term Liabilities : €7.09 Mil (As of Sep. 2024) - GuruFocus.com
WAVE Life Sciences (FRA:1U5) Dividend Payout Ratio : 0.00 (As of Sep. 2024) - GuruFocus.com
Comprehensive Market Analysis of Latest Published 9 Rare Genetic Disorders Reports | DelveInsight - GlobeNewswire Inc.
(WVE) Investment Analysis - Stock Traders Daily
Y Intercept Hong Kong Ltd Has $242,000 Stock Holdings in Wave Life Sciences Ltd. (NASDAQ:WVE) - MarketBeat
Wellington Management Group LLP Reduces Position in Wave Life Sciences Ltd. (NASDAQ:WVE) - MarketBeat
Wave Life Sciences Ltd. (NASDAQ:WVE) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Wave Life Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
WaVe Life Sciences' SWOT analysis: RNA editing pioneer's stock faces pivotal year - Investing.com Australia
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):